Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
June 02, 2024 12:30 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
June 02, 2024 11:31 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
June 02, 2024 10:55 ET
|
Seer, Inc.
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
June 02, 2024 10:00 ET
|
Nanobiotix S.A.
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024 10:00 ET
|
ALX Oncology
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024 09:01 ET
|
Celldex Therapeutics, Inc.
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
ImPact Biotech Presents Additional Interim Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
June 02, 2024 09:00 ET
|
ImPact Biotech
Promising response rate in patients with low-grade upper tract urothelial cancer (UTUC); complete response (CR) observed in 77% (10/13) of patients who completed the Induction Treatment...
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
June 02, 2024 08:56 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software...
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
June 02, 2024 08:52 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s leaders in robot development are adopting the NVIDIA Isaac™ robotics platform for the research,...
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
June 02, 2024 08:44 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that major Taiwanese electronics makers are using the company’s technology to transform their factories into more...